Katy Rezvani
M.D. Anderson Cancer Center · Imperial College Healthcare NHS Trust · Hammersmith Hospital, London, United Kingdom
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Katy Rezvani as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 07:12 UTC. Open this list on ClinicalTrials.gov
- Ph1/Ph2NCT03579927 · CAR.CD19-CD28-zeta-2A-iCasp9-IL15-Transduced Cord Blood NK Cells, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Participants With B-cell LymphomaM.D. Anderson Cancer Center · withdrawn · CD19 Positive, Mantle Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma · principal investigator
- Ph1NCT01336478 · CD56+CD3- NK Cells Following Allogeneic Stem Cell TransplantationImperial College London · withdrawn · Haematological Malignancies, Allogeneic Stem Cell Transplant, CD56+CD3- NK Cells · principal investigator
- Ph1/Ph2NCT01326273 · Autologous Cytomegalovirus (CMV) Specific CD8+ T Cells as Treatment for CMV ReactivationImperial College London · withdrawn · CMV Reactivation, Allogeneic Stem Cell Transplantation, Autologous CMV Specific CD8+ T Cells · principal investigator
- Ph2/Ph3NCT00967343 · Efficacy and Safety of a Donor Lymphocyte Preparation Depleted of Functional Host Alloreactive T-cells (ATIR) in Patients Undergoing a Peripheral Blood Stem Cell Transplant From a Related, Haploidentical DonorKiadis Pharma · terminated · Myeloid Leukemia, Lymphoblastic Leukemia, Lymphoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 07:12 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 2 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Illuminating the Immune Dynamics of Metastatic Renal Cell Carcinoma to BoneR01CA307210 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · fiscal years 2026 · $579,658 awarded in 2026Same name and institution; not confirmed by an ID
- Next Generation Engineered NK Cells for Lymphoma Patients after CD19 CAR-T Cell Failure.R01CA280827 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · fiscal years 2023 to 2026 · $370,575 awarded in 2026Same name and institution; not confirmed by an ID
- Next-Generation Engineered NK Cell Immunotherapy for Ovarian CancerP50CA281701 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · fiscal years 2023 to 2026 · $329,670 awarded in 2026Same name and institution; not confirmed by an ID
- NK Cell Engineering to Target Intracellular Antigens in AMLR01CA310933 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · fiscal years 2026 · $442,146 awarded in 2026Same name and institution; not confirmed by an ID
- TROP2-Directed CAR-NK Cells for the Immunotherapy of Pancreatic CancerR01CA288617 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · fiscal years 2024 to 2026 · $370,575 awarded in 2026Same name and institution; not confirmed by an ID
- Advancing next-generation CAR-NK therapies targeting CD5 positive T cell malignancies to the clinicR01CA303579 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · fiscal years 2025 · $1,847,485 awarded in 2025Same name and institution; not confirmed by an ID
- Project 4: Off-the-shelf engineered cord blood-derived natural killer cells for the treatment acute lymphoblastic leukemiaP50CA100632 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · fiscal years 2018 to 2023 · $293,401 awarded in 2023Same name and institution; not confirmed by an ID
- Off-the-Shelf Engineered Cord Blood NK Cells for the Treatment of Hematologic Malignancies.P01CA148600 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · fiscal years 2018 to 2022 · $493,218 awarded in 2022Same name and institution; not confirmed by an ID
- Research Training in Academic Medical OncologyT32CA009666 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · fiscal years 2020 to 2022 · $591,629 awarded in 2022Same name and institution; not confirmed by an ID
- Off-the-shelf engineered NK cells for the treatment of AMLR01CA211044 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · fiscal years 2017 to 2021 · $366,000 awarded in 2021Same name and institution; not confirmed by an ID
- Off-the-shelf Genetically Engineered Natural Killer Therapy for GlioblastomaP50CA127001 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · fiscal years 2021 · $258,822 awarded in 2021Same name and institution; not confirmed by an ID
- Hematopoietic Progenitor Cells- Cord BloodR01CA061508 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · fiscal years 2016 to 2020 · $380,000 awarded in 2020Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Experimental Medicine ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI FUNDA MERIC-BERNSTAM · fiscal years 2013 to 2026Named on NCT03579927
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 07:12 UTC. The ranking covers the 200 most relevant of 50 PubMed records, and a shared surname and initials can bring in a namesake. All 50 on PubMed
- Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors.N Engl J Med · 20201,848 citationsRCR 77.0
- 460 citationsRCR 53.4
- Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells.J Clin Invest · 2016412 citationsRCR 12.0
- 299 citationsRCR 6.4
- 296 citationsRCR 6.0
- 289 citationsRCR 8.8
- Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial.Lancet Haematol · 2023236 citationsRCR 20.8
- Similar transplantation outcomes for acute myeloid leukemia and myelodysplastic syndrome patients with haploidentical versus 10/10 human leukocyte antigen-matched unrelated and related donors.Biol Blood Marrow Transplant · 2014183 citationsRCR 6.1
- 182 citationsRCR 4.0
- Phase I study of cord blood-derived natural killer cells combined with autologous stem cell transplantation in multiple myeloma.Br J Haematol · 2017177 citationsRCR 5.3